LB PharmaceuticalsCommon Stock EBIT

LB PharmaceuticalsCommon Stock's ebit stands at $-93M as of June 2026. That is below the Healthcare sector average of $22B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

LB PharmaceuticalsCommon Stock sits lower the Healthcare benchmark ($22B) with a EBIT of $-93M. That is roughly 100.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Open the history chart to see whether LB PharmaceuticalsCommon Stock's EBIT is expanding or contracting. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how LB PharmaceuticalsCommon Stock's EBIT evolved across reporting periods, while the comparison chart places LBRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, EBIT is commonly used to spot outliers. LB PharmaceuticalsCommon Stock's reading of $-93M (sector avg $22B) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.